 LEXINGTON, Mass. and AMSTERDAM, The Netherlands, June 16, 2021 GLOBE NEWSWIRE -- uniQure N.V. NASDAQ: QURE, a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the first two patient procedures have been completed in the higher dose, second cohort of the Phase III clinical trial of AMT-130 for the treatment of Huntingtons disease. The initiation of patient enrollment in this 16-patient cohort follows a meeting last month of the trials independent Data Safety Monitoring Board DSMB that reviewed safety data for the fully enrolled first cohort of ten patients. The Phase III study is a double-blind, randomized clinical trial being conducted in the United States. To date, seven patients now have been treated with AMT-130 across both trial cohorts, and five patients have received the imitation surgery. 